Young Kwon is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Young held various leadership roles as a senior executive at Momenta Pharmaceuticals, most recently as Chief Financial and Business Officer, where he was responsible for business development, strategy, finance, investor relations, and commercial. During his tenure at […]

Dr. Lee is Chief Executive Officer of Bicycle Therapeutics and Non-Executive Director of Mestag and NodThera Ltd. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full […]

Dr. Hamer is a Managing General Partner at DCVC Bio, a San Francisco venture capital fund focused on building the next generation of life science companies. He has held positions as Managing Partner and Founder of Monsanto Growth Ventures and Managing Director and Entrepreneur-in-Residence at Burrill & Co. Prior to venture capital, John held senior […]

Dr. Levin joined RA Capital Management in 2015, is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the […]

Professor Ashrafian is a Managing Partner at SV Health Investors and co-founded Alchemab in 2019. Alongside Alchemab he has founded six other SV companies; Cellinta, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics and Imbria. Previously, Houman co-founded the […]